{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:10:20Z","timestamp":1774523420827,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Northern Ireland Kidney Research Fund","award":["R229NUR"],"award-info":[{"award-number":["R229NUR"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kidney cachexia is a debilitating and under-recognised complication of advanced chronic kidney disease (CKD), characterised by unintentional weight loss, muscle wasting, inflammation, and reduced functional capacity. Its profound impact on morbidity, quality of life, and healthcare utilisation underscores the need for targeted, implementable interventions. The multicomponent implementation strategy for a multi-modal, integrated, exercise, anti-inflammatory, and dietary advice (MMIEAD) intervention seeks to address this gap. Guided by the practical, robust implementation, and sustainability model (PRISM), which incorporates reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) outcomes, this study aims to ensure strong intervention\u2013context alignment to support future scalability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The MMIEAD model will be evaluated by determining patient eligibility and recruitment rates, identifying intervention retention and adherence, assessing key statistical and methodological considerations to inform optimal study design and data collection burden, conducting a qualitative process evaluation to examine intervention acceptability and practicality, and determining the feasibility of undertaking a definitive economic evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This mixed-methods study consists of three phases. Phase 1 will deliver and evaluate a 12-week multimodal intervention using a feasibility cluster randomised controlled trial (cRCT) design. Phase 2 will undertake a qualitative process evaluation with healthcare practitioners (HCPs) and patients. Phase 3 will assess the feasibility of conducting a full economic evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      Patients will be eligible if they have haemodialysis-dependent CKD stage 5 for more than 3 months, have experienced unintentional weight loss of at least 5% in the previous 12 months, or have a body mass index &lt;20 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , and are aged over 18 years. HCPs will be eligible if they are members of the multidisciplinary healthcare team for more than 3 months and have had exposure to the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting and randomisation<\/jats:title>\n                    <jats:p>The study will be conducted across four outpatient haemodialysis units in the UK. Two sites have been randomly allocated to the intervention group and two to the control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Sample<\/jats:title>\n                    <jats:p>For phases 1 and 3, a total of 40 patient participants will be recruited (10 per intervention site and 10 per control site). For phase 2, qualitative data will be collected through interviews with approximately 15 patients and interviews or focus groups with 15 HCPs across all sites. Recruitment commenced on 08.09.25 following ethical approval (REC reference: 25\/NI\/0069).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Using multi-method analyses informed by PRISM\/RE-AIM dimensions, we will generate evidence on the feasibility, acceptability, and contextual fit of the MMIEAD intervention to prepare for a definitive UK-wide multi-site cRCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Trial registration number NCT07107087 (30 July 2025).\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT07107087\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT07107087<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40814-026-01784-z","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:53:12Z","timestamp":1771487592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-modal integrated intervention combining exercise, anti-inflammatory, and dietary advice (MMIEAD) for adults with kidney cachexia: protocol for a mixed-methods feasibility cluster randomised controlled trial and process evaluation"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-862X","authenticated-orcid":false,"given":"Joanne","family":"Reid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Slee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"McKeaveney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander P.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki","family":"Adell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faizan","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damian","family":"Fogarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Fouque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oonagh","family":"Gooding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"McKinley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Magee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"NICRN Clinical Research Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Noble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Seres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Swaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles","family":"Witham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"1784_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12167","author":"S von Haehling","year":"2016","unstructured":"von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle. 2016. https:\/\/doi.org\/10.1002\/jcsm.12167.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"1784_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/MCO.0000000000001022","volume":"27","author":"A Slee","year":"2024","unstructured":"Slee A, Reid J. Exercise and nutrition interventions for renal cachexia. Curr Opin Clin Nutr Metab Care. 2024;27(3):219\u201325. https:\/\/doi.org\/10.1097\/MCO.0000000000001022.","journal-title":"Curr Opin Clin Nutr Metab Care."},{"issue":"1","key":"1784_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.21037\/apm.2018.12.08","volume":"8","author":"J Crawford","year":"2019","unstructured":"Crawford J. What are the criteria for response to cachexia treatment? Ann Palliat Med. 2019;8(1):43\u20139.","journal-title":"Ann Palliat Med"},{"issue":"5","key":"1784_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1758834017698643","volume":"9","author":"Z Aversa","year":"2017","unstructured":"Aversa Z, Costelli P, Muscaritoli M. Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther Adv Med Oncol. 2017;9(5):369\u201382. https:\/\/doi.org\/10.1177\/1758834017698643.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"1784_CR5","doi-asserted-by":"publisher","first-page":"CD015749","DOI":"10.1002\/14651858.CD015749.pub2","volume":"3","author":"J Reid","year":"2025","unstructured":"Reid J, Blair C, Dempster M, McKeaveney C, Slee A, Fitzsimons D. Multimodal interventions for cachexia management. Cochrane Database Syst Rev. 2025;3(3):CD015749. https:\/\/doi.org\/10.1002\/14651858.CD015749.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1784_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/advances\/nmaa111","volume":"12","author":"C McKeaveney","year":"2021","unstructured":"McKeaveney C, Maxwell P, Noble H, Reid J. A Critical review of multimodal interventions for cachexia. Adv Nutr. 2021;12(2):523\u201332. https:\/\/doi.org\/10.1093\/advances\/nmaa111.","journal-title":"Adv Nutr"},{"key":"1784_CR7","doi-asserted-by":"publisher","unstructured":"Brownson RC, Shelton RC, Geng EH, Glasgow RE. Revisiting concepts of evidence in implementation science. Implement Sci. 2022;17(1):26. https:\/\/doi.org\/10.1186\/s13012-022-01201-y.","DOI":"10.1186\/s13012-022-01201-y"},{"key":"1784_CR8","doi-asserted-by":"publisher","unstructured":"McKeaveney C, Slee A, Adamson G, Davenport A, Farrington K, Fouque D, et al. Using a generic definition of cachexia in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study. Nephrol Dial Transplant. 2021;36(10):1919\u201326. https:\/\/doi.org\/10.1093\/ndt\/gfaa174.","DOI":"10.1093\/ndt\/gfaa174"},{"issue":"1","key":"1784_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/jorc.12301","volume":"46","author":"C Mckeaveney","year":"2020","unstructured":"Mckeaveney C, Noble H, de Barbieri I, Strini V, Maxwell AP, Reid J. Awareness, understanding and treatment practices when managing cachexia in end\u2010stage kidney disease. J Ren Care. 2020;46(1):35\u201344.","journal-title":"J Ren Care"},{"key":"1784_CR10","doi-asserted-by":"publisher","first-page":"100235","DOI":"10.1016\/j.ijnsa.2024.100235","volume":"7","author":"C Blair","year":"2024","unstructured":"Blair C, Shields J, Mullan R, Johnston W, Davenport A, Fouque D, et al. The lived experience of renal cachexia: an interpretive phenomenological analysis. Int J Nurs Stud Adv. 2024;7:100235.","journal-title":"Int J Nurs Stud Adv"},{"key":"1784_CR11","doi-asserted-by":"publisher","unstructured":"Noor H, Reid J, Slee A. Resistance exercise and nutritional interventions for augmenting sarcopenia outcomes in chronic kidney disease: a narrative review. J Cachexia Sarcopenia Muscle. 2021;12(6):1621\u201340. https:\/\/doi.org\/10.1002\/jcsm.12791.","DOI":"10.1002\/jcsm.12791"},{"key":"1784_CR12","doi-asserted-by":"crossref","unstructured":"Argil\u00e9s JM, Stemmler B, L\u00f3pez-Soriano FJ, Busquets S. Inter-tissue communication in cancer cachexia. Nat Rev Endocrinol. 2019;15(1):9\u201320.","DOI":"10.1038\/s41574-018-0123-0"},{"key":"1784_CR13","doi-asserted-by":"publisher","unstructured":"Di Girolamo FG, Guadagni M, Fiotti N, Situlin R, Biolo G. Contraction and nutrition interaction promotes anabolism in cachectic muscle. Curr Opin Clin Nutr Metab Care. 2019;22(1):60\u20137. https:\/\/doi.org\/10.1097\/mco.0000000000000527.","DOI":"10.1097\/mco.0000000000000527"},{"key":"1784_CR14","doi-asserted-by":"publisher","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"1784_CR15","doi-asserted-by":"publisher","unstructured":"Hall CC, Cook J, Maddocks M, Skipworth RJE, Fallon M, Laird BJ. Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: a systematic review. Support Care Cancer. 2019;27(7):2371\u201384. https:\/\/doi.org\/10.1007\/s00520-019-04749-6.","DOI":"10.1007\/s00520-019-04749-6"},{"key":"1784_CR16","doi-asserted-by":"publisher","unstructured":"Koppe L, Fouque D, Kalantar-Zadeh K. Kidney cachexia or protein-energy wasting in chronic kidney disease: factsand numbers. J Cachexia Sarcopenia Muscle. 2019;10(3):479\u201384. https:\/\/doi.org\/10.1002\/jcsm.12421. Epub 2019 Apr 12.PMID: 30977979; PMCID: PMC6596400.","DOI":"10.1002\/jcsm.12421"},{"key":"1784_CR17","doi-asserted-by":"publisher","unstructured":"Del Fabbro E. Combination therapy in cachexia. Ann Palliat Med. 2019;8(1):59\u201366. https:\/\/doi.org\/10.21037\/apm.2018.08.05.","DOI":"10.21037\/apm.2018.08.05"},{"issue":"1","key":"1784_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-15-267","volume":"15","author":"MJ De Silva","year":"2014","unstructured":"De Silva MJ, Breuer E, Lee L, Asher L, Chowdhary N, Lund C, et al. Theory of change: a theory-driven approach to enhance the Medical Research Council\u2019s framework for complex interventions. Trials. 2014;15(1):1\u201313.","journal-title":"Trials."},{"issue":"2","key":"1784_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/09614524.2015.1003532","volume":"25","author":"G Prinsen","year":"2015","unstructured":"Prinsen G, Nijhof S. Between logframes and theory of change: reviewing debates and a practical experience. Dev Pract. 2015;25(2):234\u201346.","journal-title":"Dev Pract"},{"key":"1784_CR20","doi-asserted-by":"publisher","unstructured":"Blair C, Slee A, Davenport A, Fouque D, Johnston W, Kalantar-Zadeh K, Maxwell P, McKeaveney C, Mullan R, Noble H, Porter S, Seres D, Shields J, Swaine I, Witham M, Reid J. Developing an Evidence and Theory Based Multimodal Integrative Intervention for the Management of Renal Cachexia: A Theory of Change. Healthcare (Basel). 2022;10(12):2344. https:\/\/doi.org\/10.3390\/healthcare10122344. PMID: 36553868; PMCID: PMC9777598.","DOI":"10.3390\/healthcare10122344"},{"key":"1784_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1655","volume":"337","author":"P Craig","year":"2008","unstructured":"Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655. https:\/\/doi.org\/10.1136\/bmj.a1655.","journal-title":"BMJ"},{"key":"1784_CR22","doi-asserted-by":"publisher","unstructured":"Hoff mann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. https:\/\/doi.org\/10.1136\/bmj.g1687.","DOI":"10.1136\/bmj.g1687"},{"key":"1784_CR23","doi-asserted-by":"publisher","unstructured":"Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, et al. SPIRIT 2025 statement: Updated guideline for protocols of randomised trials. PLoS Med. 2025;22(4):e1004589. https:\/\/doi.org\/10.1371\/journal.pmed.1004589.","DOI":"10.1371\/journal.pmed.1004589"},{"key":"1784_CR24","doi-asserted-by":"crossref","unstructured":"Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. Bmj. 2008;337.","DOI":"10.1136\/bmj.a1655"},{"key":"1784_CR25","doi-asserted-by":"publisher","unstructured":"Higginson IJ, Evans CJ, Grande G, Preston N, Morgan M, McCrone P, et al. Evaluating complex interventions in end of life care: the MORE Care statement on good practice generated by a synthesis of transparent expert consultations and systematic reviews. BMC Med. 2013;11(1):111. https:\/\/doi.org\/10.1186\/1741-7015-11-111.","DOI":"10.1186\/1741-7015-11-111"},{"issue":"1","key":"1784_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-024-02130-6","volume":"23","author":"MP Jolles","year":"2024","unstructured":"Jolles MP, Fort MP, Glasgow RE. Aligning the planning, development, and implementation of complex interventions to local contexts with an equity focus: application of the PRISM\/RE-AIM framework. Int J Equity Health. 2024;23(1):41. https:\/\/doi.org\/10.1186\/s12939-024-02130-6.","journal-title":"Int J Equity Health"},{"key":"1784_CR27","doi-asserted-by":"publisher","DOI":"10.5888\/pcd15.170271","volume":"15","author":"RE Glasgow","year":"2018","unstructured":"Glasgow RE, Estabrooks PE. Pragmatic applications of RE-AIM for health care initiatives in community and clinical settings. Prev Chronic Dis. 2018;15:E02. https:\/\/doi.org\/10.5888\/pcd15.170271.","journal-title":"Prev Chronic Dis"},{"key":"1784_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.04.025","volume":"283","author":"MS Bauer","year":"2020","unstructured":"Bauer MS, Kirchner J. Implementation science: what is it and why should I care? Psychiatry Res. 2020;283:112376. https:\/\/doi.org\/10.1016\/j.psychres.2019.04.025.","journal-title":"Psychiatry Res"},{"key":"1784_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0000000000000830","author":"A Slee","year":"2022","unstructured":"Slee A, Reid J. Disease-related malnutrition in chronic kidney disease. Curr Opin Clin Nutr Metab Care. 2022. https:\/\/doi.org\/10.1097\/MCO.0000000000000830.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"4","key":"1784_CR30","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.clnu.2021.01.028","volume":"40","author":"E Fiaccadori","year":"2021","unstructured":"Fiaccadori E, Sabatino A, Barazzoni R, Carrero JJ, Cupisti A, De Waele E, et al. ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clin Nutr. 2021;40(4):1644\u201368. https:\/\/doi.org\/10.1016\/j.clnu.2021.01.028.","journal-title":"Clin Nutr"},{"issue":"4","key":"1784_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/jcsm.12083","volume":"6","author":"KCH Fearon","year":"2015","unstructured":"Fearon KCH, Argiles JM, Baracos VE, Bernabei R, Coats AJS, Crawford J, et al. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle. 2015;6(4):272\u20134. https:\/\/doi.org\/10.1002\/jcsm.12083.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"1784_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/nur.10088","volume":"26","author":"S Ward","year":"2003","unstructured":"Ward S, Donovan HS, Serlin RC. An alternative view on \u201can alternative paradigm.\u201d Res Nurs Health. 2003;26(3):256.","journal-title":"Res Nurs Health"},{"key":"1784_CR33","unstructured":"De Silva M, Breuer E, Lee L, Lund C, Patel V. Theory of change: a theorydriven approach to the MRC framework for complex interventions. Poster London: London School of Hygiene & Tropical Medicine, Department of International Development. 2012."},{"key":"1784_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00788","volume":"8","author":"M-S Yoon","year":"2017","unstructured":"Yoon M-S. mTOR as a key regulator in maintaining skeletal muscle mass. Front Physiol. 2017;8:788.","journal-title":"Front Physiol"},{"issue":"7","key":"1784_CR35","volume":"31","author":"M Brown","year":"2023","unstructured":"Brown M, Murphy MH, McAneney H, McBride K, Crawford F, Cole A, et al. Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT). Support Care Cancer. 2023;31(7):442.","journal-title":"Support Care Cancer"},{"key":"1784_CR36","doi-asserted-by":"publisher","unstructured":"Ikizler TA, Himmelfarb J. Muscle wasting in kidney disease: Let's get physical. J Am Soc Nephrol. 2006;17(8):2097\u20138. https:\/\/doi.org\/10.1681\/ASN.2006060629. Epub 2006 Jul 12. PMID: 16837638.","DOI":"10.1681\/ASN.2006060629"},{"issue":"3","key":"1784_CR37","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","volume":"76","author":"TA Ikizler","year":"2020","unstructured":"Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero J-J, Chan W, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis. 2020;76(3):S1\u2013107. https:\/\/doi.org\/10.1053\/j.ajkd.2020.05.006.","journal-title":"Am J Kidney Dis"},{"key":"1784_CR38","doi-asserted-by":"publisher","unstructured":"Zhang C, Ge C, Wang J, Sun D. Effects of fish oil during hemodialysis on nutritional status and quality of life: a randomized double-blinded trial. Food Nutr Res. 2020;64. https:\/\/doi.org\/10.29219\/fnr.v64.4450.","DOI":"10.29219\/fnr.v64.4450"},{"issue":"10","key":"1784_CR39","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s11255-017-1643-6","volume":"49","author":"H Zakaria","year":"2017","unstructured":"Zakaria H, Mostafa TM, El-Azab GA, Abd El Wahab AM, Elshahawy H, Sayed-Ahmed NA. The impact of fish oil and wheat germ oil combination on mineral-bone and inflammatory markers in maintenance hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial. Int Urol Nephrol. 2017;49(10):1851\u20138. https:\/\/doi.org\/10.1007\/s11255-017-1643-6.","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"1784_CR40","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1177\/0962280215588241","volume":"25","author":"AL Whitehead","year":"2016","unstructured":"Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016;25(3):1057\u201373.","journal-title":"Stat Methods Med Res"},{"issue":"5","key":"1784_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232076","volume":"15","author":"A Soundy","year":"2020","unstructured":"Soundy A, Guest G, Namey E, Chen M. A simple method to assess and report thematic saturation in qualitative research. PLoS One. 2020;15(5):e0232076. https:\/\/doi.org\/10.1371\/journal.pone.0232076.","journal-title":"PLoS One"},{"issue":"1","key":"1784_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MLR.0000000000001664","volume":"60","author":"JA Teresi","year":"2022","unstructured":"Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for designing and evaluating feasibility pilot studies. Med Care. 2022;60(1):95\u2013103. https:\/\/doi.org\/10.1097\/MLR.0000000000001664.","journal-title":"Med Care"},{"issue":"3","key":"1784_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jphys.2016.05.008","volume":"62","author":"CE Roffman","year":"2016","unstructured":"Roffman CE, Buchanan J, Allison GT. Charlson comorbidities index. J Physiother. 2016;62(3):171. https:\/\/doi.org\/10.1016\/j.jphys.2016.05.008.","journal-title":"J Physiother"},{"key":"1784_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-016-0763-7","volume":"14","author":"R Pavasini","year":"2016","unstructured":"Pavasini R, Guralnik J, Brown JC, Di Bari M, Cesari M, Landi F, et al. Short physical performance battery and all-cause mortality: systematic review and meta-analysis. BMC Med. 2016;14:1\u20139.","journal-title":"BMC Med"},{"issue":"5","key":"1784_CR45","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/ageing\/afl041","volume":"35","author":"DB Rolfson","year":"2006","unstructured":"Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K. Validity and reliability of the Edmonton Frail Scale. Age Ageing. 2006;35(5):526\u20139. https:\/\/doi.org\/10.1093\/ageing\/afl041.","journal-title":"Age Ageing"},{"issue":"6","key":"1784_CR46","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793\u20139. https:\/\/doi.org\/10.1016\/j.clnu.2008.06.013.","journal-title":"Clin Nutr"},{"issue":"10","key":"1784_CR47","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1093\/ndt\/gfaa174","volume":"36","author":"C McKeaveney","year":"2021","unstructured":"McKeaveney C, Slee A, Adamson G, Davenport A, Farrington K, Fouque D, et al. Using a generic definition of cachexia in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study. Nephrol Dial Transplant. 2021;36(10):1919\u201326. https:\/\/doi.org\/10.1093\/ndt\/gfaa174.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1784_CR48","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1093\/ajcn\/34.11.2530","volume":"34","author":"CW Bishop","year":"1981","unstructured":"Bishop CW, Bowen P, Ritchey S. Norms for nutritional assessment of American adults by upper arm anthropometry. Am J Clin Nutr. 1981;34(11):2530\u20139.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"1784_CR49","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/ndt\/gfq497","volume":"26","author":"M Stosovic","year":"2011","unstructured":"Stosovic M, Stanojevic M, Simic-Ogrizovic S, Jovanovic D, Djukanovic L. The predictive value of anthropometric parameters on mortality in haemodialysis patients. Nephrol Dial Transplant. 2011;26(4):1367\u201374.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1784_CR50","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.jrn.2019.09.004","volume":"30","author":"A Slee","year":"2020","unstructured":"Slee A, McKeaveney C, Adamson G, Davenport A, Farrington K, Fouque D, et al. Estimating the prevalence of muscle wasting, weakness, and sarcopenia in hemodialysis patients. J Ren Nutr. 2020;30(4):313\u201321. https:\/\/doi.org\/10.1053\/j.jrn.2019.09.004.","journal-title":"J Ren Nutr"},{"issue":"4","key":"1784_CR51","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/ageing\/afr051","volume":"40","author":"HC Roberts","year":"2011","unstructured":"Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423\u20139. https:\/\/doi.org\/10.1093\/ageing\/afr051.","journal-title":"Age Ageing"},{"issue":"1","key":"1784_CR52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16\u201331.","journal-title":"Age Ageing"},{"issue":"6","key":"1784_CR53","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","volume":"24","author":"D Cella","year":"2002","unstructured":"Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24(6):547\u201361.","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"1784_CR54","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cncr.20777","volume":"103","author":"DJ Brown","year":"2005","unstructured":"Brown DJ, McMillan DC, Milroy R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer. 2005;103(2):377\u201382.","journal-title":"Cancer"},{"issue":"18","key":"1784_CR55","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1002\/cncr.30134","volume":"122","author":"YW Leung","year":"2016","unstructured":"Leung YW, Brown C, Cosio AP, Dobriyal A, Malik N, Pat V, et al. Feasibility and diagnostic accuracy of the Patient-Reported Outcomes Measurement Information System (PROMIS) item banks for routine surveillance of sleep and fatigue problems in ambulatory cancer care. Cancer. 2016;122(18):2906\u201317. https:\/\/doi.org\/10.1002\/cncr.30134.","journal-title":"Cancer"},{"key":"1784_CR56","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1023\/A:1016670403148","volume":"9","author":"J Ribaudo","year":"2000","unstructured":"Ribaudo J, Cella D, Hahn E, Lloyd S, Tchekmedyian N, Roenn JV, et al. Re-validation and shortening of the functional Assessmentof anorexia\/Cachexia therapy (FAACT) questionnaire. Qual Life Res. 2000;9:1137\u201346.","journal-title":"Qual Life Res"},{"issue":"3","key":"1784_CR57","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/01635581.2018.1506488","volume":"71","author":"JG Turcott","year":"2019","unstructured":"Turcott JG, Onate-Ocana LF, Soca-Chafre G, Ramirez-Tirado LA, Flores-Estrada D, Zatarain-Barron ZL, et al. FAACT-anorexia cachexia scale: cutoff value for anorexia diagnosis in advanced non-small cell lung cancer patients. Nutr Cancer. 2019;71(3):409\u201317. https:\/\/doi.org\/10.1080\/01635581.2018.1506488.","journal-title":"Nutr Cancer"},{"key":"1784_CR58","unstructured":"Brouwer W. The EQ-5D-5L valuation set for England: a view from the side. 2019."},{"issue":"9","key":"1784_CR59","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10198-014-0664-7","volume":"16","author":"F Yang","year":"2015","unstructured":"Yang F, Lau T, Lee E, Vathsala A, Chia KS, Luo N. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD). Eur J Health Econ. 2015;16(9):1019\u201326. https:\/\/doi.org\/10.1007\/s10198-014-0664-7.","journal-title":"Eur J Health Econ"},{"key":"1784_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1258","volume":"350","author":"GF Moore","year":"2015","unstructured":"Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ. 2015;350:h1258. https:\/\/doi.org\/10.1136\/bmj.h1258.","journal-title":"BMJ"},{"issue":"1","key":"1784_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-06364-w","volume":"21","author":"K Garfield","year":"2021","unstructured":"Garfield K, Husbands S, Thorn JC, Noble S, Hollingworth W. Development of a brief, generic, modular resource-use measure (ModRUM): cognitive interviews with patients. BMC Health Serv Res. 2021;21(1):371.","journal-title":"BMC Health Serv Res"},{"key":"1784_CR62","unstructured":"Act DP. 2018, c. 12. Available from: https:\/\/www.legislation.gov.uk\/ukpga\/2018\/12\/contents\/enacted."},{"issue":"OCE3","key":"1784_CR63","doi-asserted-by":"publisher","first-page":"E796","DOI":"10.1017\/S002966512000782X","volume":"79","author":"H Al-Sehaim","year":"2020","unstructured":"Al-Sehaim H, Douglas F. A Class Act-revising food classifications to enable automated assessment of compliance with food-based dietary guidelines. Proc Nutr Soc. 2020;79(OCE3):E796.","journal-title":"Proc Nutr Soc"},{"issue":"222","key":"1784_CR64","first-page":"248","volume":"2015","author":"V Clarke","year":"2015","unstructured":"Clarke V, Braun V, Hayfield N. Thematic analysis. Qual Psychol Pract Guide Res Methods. 2015;2015(222):248.","journal-title":"Qual Psychol Pract Guide Res Methods"},{"issue":"1","key":"1784_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-14-15","volume":"14","author":"A Grant","year":"2013","unstructured":"Grant A, Treweek S, Dreischulte T, Foy R, Guthrie B. Process evaluations for cluster-randomised trials of complex interventions: a proposed framework for design and reporting. Trials. 2013;14(1):15.","journal-title":"Trials"},{"key":"1784_CR66","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.pmedr.2017.04.002","volume":"6","author":"J Forman","year":"2017","unstructured":"Forman J, Heisler M, Damschroder LJ, Kaselitz E, Kerr EA. Development and application of the RE-AIM QuEST mixed methods framework for program evaluation. Prev Med Rep. 2017;6:322\u20138. https:\/\/doi.org\/10.1016\/j.pmedr.2017.04.002.","journal-title":"Prev Med Rep"},{"issue":"1","key":"1784_CR67","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jen.2018.11.004","volume":"45","author":"MD Moon","year":"2019","unstructured":"Moon MD. Triangulation: a method to increase validity, reliability, and legitimation in clinical research. J Emerg Nurs. 2019;45(1):103\u20135. https:\/\/doi.org\/10.1016\/j.jen.2018.11.004.","journal-title":"J Emerg Nurs"},{"key":"1784_CR68","unstructured":"Hunter R, Shearer J. Cost-consequences analysis-an underused method of economic evaluation. National Institute for Health Research. 2014:4\u20135. https:\/\/www.rds-london.nihr.ac.uk\/resources\/health-economics\/cost-consequences-analysis-an-underused-method\/%23%3a%7E:text=Cost%2Dconsequences%20analysis%20(CCA. Accessed 20 July 2025."},{"issue":"1","key":"1784_CR69","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s40814-020-00634-w","volume":"6","author":"N Pearson","year":"2020","unstructured":"Pearson N, Naylor P-J, Ashe MC, Fernandez M, Yoong SL, Wolfenden L. Guidance for conducting feasibility and pilot studies for implementation trials. Pilot Feasibility Stud. 2020;6(1):167. https:\/\/doi.org\/10.1186\/s40814-020-00634-w.","journal-title":"Pilot Feasibility Stud"},{"issue":"4","key":"1784_CR70","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/pst.185","volume":"4","author":"SA Julious","year":"2005","unstructured":"Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287\u201391.","journal-title":"Pharm Stat"},{"issue":"3","key":"1784_CR71","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jclinepi.2011.07.011","volume":"65","author":"J Sim","year":"2012","unstructured":"Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012;65(3):301\u20138.","journal-title":"J Clin Epidemiol"},{"key":"1784_CR72","doi-asserted-by":"crossref","unstructured":"Lancaster GA. Pilot and feasibility studies come of age! : BioMed Central; 2015. pp. 1-4","DOI":"10.1186\/2055-5784-1-1"},{"issue":"1","key":"1784_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-67","volume":"10","author":"M Arain","year":"2010","unstructured":"Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol. 2010;10(1):67.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1784_CR74","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/2229-3485.167097","volume":"6","author":"S Kannan","year":"2015","unstructured":"Kannan S, Gowri S. Pilot studies: are they appropriately reported? Perspect Clin Res. 2015;6(4):207\u201310.","journal-title":"Perspect Clin Res"},{"key":"1784_CR75","doi-asserted-by":"publisher","unstructured":"Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239. https:\/\/doi.org\/10.1136\/bmj.i5239. PMID: 27777223; PMCID: PMC5076380.","DOI":"10.1136\/bmj.i5239"},{"key":"1784_CR76","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40814-015-0026-y","volume":"1","author":"A O\u2019Cathain","year":"2015","unstructured":"O\u2019Cathain A, Hoddinott P, Lewin S, Thomas KJ, Young B, Adamson J, et al. Maximising the impact of qualitative research in feasibility studies for randomised controlled trials: guidance for researchers. Pilot Feasibility Stud. 2015;1:32. https:\/\/doi.org\/10.1186\/s40814-015-0026-y.","journal-title":"Pilot Feasibility Stud"},{"issue":"10","key":"1784_CR77","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25(10):1229\u201345. https:\/\/doi.org\/10.1080\/08870440903194015.","journal-title":"Psychol Health."},{"issue":"5","key":"1784_CR78","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jcsm.12201","volume":"8","author":"TS Solheim","year":"2017","unstructured":"Solheim TS, Laird BJA, Balstad TR, Stene GB, Bye A, Johns N, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017;8(5):778\u201388. https:\/\/doi.org\/10.1002\/jcsm.12201.","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"1784_CR79","doi-asserted-by":"publisher","unstructured":"Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655. https:\/\/doi.org\/10.1136\/bmj.a1655. PMID: 18824488; PMCID: PMC2769032.","DOI":"10.1136\/bmj.a1655"}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-026-01784-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-026-01784-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-026-01784-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:28:22Z","timestamp":1774520902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40814-026-01784-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1784"],"URL":"https:\/\/doi.org\/10.1186\/s40814-026-01784-z","relation":{},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Recruitment commenced on 08.09.25, and ethical approval is in place for study commencement (REC reference: 25\/NI\/0069).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}